ALB and diabetic kidney disease: Hirakawa et al. (99) integrated untargeted metabolomic profiles of plasma and urine from DKD patients with ML and found that systolic blood pressure, urine albumin-to-creatinine ratio (uACR), and certain metabolites (such as urinary N-methylproline, NMP) could serve as candidate biomarkers; however, these metabolites still require external validation.